Read + Share
Amedeo Smart
Independent Medical Education
Alping P, Askling J, Burman J, Fink K, et al. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients. Ann Neurol 2020 Feb 13. doi: 10.1002/ana.25701.PMID: 32056253
Email
LinkedIn
Facebook
Twitter
Privacy Policy